The executive committee is made up of our VPs and Principals, who provide technical and strategic leadership to our teams and projects

Alexis Kuchins

US Head of Business Development

Alexis joined BresMed in 2019 with 20+ years of diverse healthcare and life sciences industry experience, having worked in sales, business development and customer relationship development on both the client and consulting sides of the business.

Alexis understands the role that real world evidence and outcomes play in payer and practitioner decisions, and she draws from a breadth of experience to help clients to define, develop and execute successful health economic and outcomes research (HEOR) strategies.

In her current role as US Head of Business Development, Alexis works closely with the different practice areas within BresMed to identify market needs and opportunities for growth with existing and new clients.

Ann-Marie Chapman

Head of Insight

Ann-Marie joined BresMed in 2014 and has over 18 years of experience in health economics and outcomes research across the consultancy, pharmaceutical and medical technology industries.

Ann-Marie has wide-ranging experience in supporting health technology assessment submissions, new product implementation and stakeholder engagement with appropriate value messages.

Anne-Marie Barnes

Director, Consulting

Annie joined BresMed in 2014 after working in a strategic healthcare communications agency for over 6 years. Annie also has a strong biological research background, with a PhD in Pharmacology and 8 years’ experience in academic research; she has published seven scientific research papers in peer-reviewed journals.

At BresMed, Annie has led and managed a wide range of multi-workstream projects including HTA submissions to NICE, SMC and NCPE. She also has extensive experience in the management and delivery of a range of market access projects. Along with day-to-day management of large multi-team projects, Annie also supports the technical teams and inputs into the overall direction and strategy of these often large and complex projects.

Catherine Rycroft

Director, Clinical Evidence Review & Head of Value Communication Services

Catherine joined BresMed in 2014 and has over 13 years of consultancy experience in market access, health economics and outcomes research, and medical communications.

She has a background in biological research, a PhD in Microbiology from the University of Reading, and spent 4 years working in molecular biology research for a biotech start-up. Catherine has a strong publication record, and extensive experience in medical writing, preparing market access deliverables (including global value dossiers, health technology assessment dossiers and systematic, structured and targeted literature reviews), and developing communication pieces such as manuscripts, slide sets, abstracts, posters and newsletters.

Catherine is part of our Clinical Evidence Review team and has been instrumental in developing the global value dossier arm of the business, along with associated value communication services.

Catriona Crossan

Principal Health Economist

Catriona joined BresMed in early 2017. She has over 7 years’ prior experience working with the Health Economic Research group at Brunel University, London, including as part of a NICE Evidence Review Group, where she conducted and critiqued economic evaluations for multiple disease areas.

She offers vast experience in the development and evaluation of cost-effectiveness models and has several publications in the areas of liver and cardiovascular disease.

Catriona has also been involved in several collaborations including an evaluation of non-invasive diagnostic tests, the findings of which contributed to World Health Organization guidelines.

Since joining BresMed, Catriona has increased her knowledge of the regulatory framework and requirements for health technology assessment submissions in Ireland.

Chrissy Lowry

Head of Health Economics Analysis

Chrissy joined BresMed in 2010 with a background in mathematics, and since April 2018 she has led the Health Economics Analysis team. She has experience in leading health economic modelling and HTA submissions to NICE, the SMC, the NCPE and the TLV, as well as developing and leading projects involving early economic models and global economic models.

Chrissy has expertise in the field of ophthalmology, having led projects across a wide range of ophthalmological indications.

Elaine Tate

Head of Commercial

Elaine joined BresMed in 2012 and has vast experience covering the entire pharmaceutical R&D process. During her career of over 30 years, she has worked at Wellcome Research Laboratories, subsidiaries of Serono and Novartis, R&D software companies and in contract research and consultancy.

Elaine supports the BresMed board in the areas of business development, business planning, contracting and compliance.

Elizabeth Thurgar

Director, Health Economics Analysis

Elizabeth joined BresMed in 2016 and has worked as a health economist for over 8 years. She has also worked as a management consultant (with a focus on health) and a government economist (Civil Service Fast Stream).

Elizabeth has experience working with pharmaceutical firms to develop health technology assessment submissions to NICE and the SMC. She also has experience in designing and building budget impact models and value proposition tools. Most recently, she worked as a member of a Technology Assessment Group for NICE, critiquing manufacturer submissions for single technology appraisals and multiple technology appraisals.

Frank van Hees

Principal Health Economist

Frank joined BresMed as a Health Economist in January 2016 and was promoted to Senior Health Economist in October 2016 and to Principal Health Economist in April 2019. He has a BSc in Biomedical Sciences, an MSc in Biomedical Sciences (major: Epidemiology, minor: Health Technology Assessment), a postgraduate certificate in Health Economics and a PhD in Health Economics/ Decision Analytic Modelling. He has a thorough understanding of CE modelling and strong analytical, methodological and strategic skills.

Before Frank joined BresMed, he worked as an Epidemiologist/ Health Economist at the Erasmus University Medical Centre, where he led several studies on the cost effectiveness of CRC screening commissioned by a variety of institutions such as the Dutch National Institute for Public Health and the Environment and the U.S. National Cancer Institute.

James Horscroft

Principal Insight Analyst

James joined BresMed in 2016 and specialises in expert elicitation and rare diseases. During his PhD, he worked in ideation and innovation of drugs for orphan metabolic diseases and conducted pre-clinical studies investigating potential treatments for obesity and ischaemia/reperfusion injury.

James has worked on HTA submissions, including submissions to NICE’s Highly Specialised Technologies Committee. He has also provided strategic input into market access planning and led expert elicitation projects involving surveys, interviews and Delphi panels relating to a range of therapeutic areas including immuno-oncology, ophthalmology and orphan diseases.

Jane Moorhouse

Principal Insight Analyst

Jane joined BresMed in 2017 with over 5 years of experience in market access and healthcare consultancy. She has worked on a range of project types, including stakeholder research, value communications, market opportunity and early value assessments, and systematic and non-systematic evidence reviews.

Jane has an academic background, having completed a PhD and postdoctoral research in molecular cell biology at the University of Manchester. She also has a Master’s degree in biochemistry from the University of Oxford.

Karl Patterson

Principal Health Economist

Karl originally joined BresMed as part of the Editorial team in February 2015, after obtaining a PhD in molecular oncology, studying chemotherapies and DNA damage in bladder cancer. Karl then moved to the Health Economics Analysis team, where he now leads the designing, building and reviewing of economic models (ranging from early feasibility analyses to global models) and health technology assessment (HTA) submissions for the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the National Centre for Pharmacoeconomics (NCPE).

Karl has experience in a number of different oncology indications, including urothelial, colorectal, liver, melanoma, myeloma, lung and renal cancer, and has supported reimbursement efforts in multiple markets.

Linda Murphy

Director, Insight

Linda joined BresMed in 2017 as part of the Insight team. She has over 7 years of HTA experience with the HIQA in Ireland and over a decade of academic and industry experience in medical devices and bioengineering research and development, design control and risk management.

Linda has applied her wide-ranging medical technology knowledge to HTA and gained experience of all aspects of HTA, including systematic literature review, stakeholder engagement, economic modelling, ethical analysis and HTA guideline development.

Lisa Cox

Head of Consulting

Lisa joined BresMed in 2012 and has over 10 years of consultancy experience in healthcare communications and outcomes research, and over 12 years of project management experience. She has worked on more than 50 submissions to UK health technology assessment (HTA) agencies.

Lisa takes a lead role on complex HTA projects, drawing on her experience in the industry, a clinical background and her project management skills to manage and deliver multifaceted projects, defining project strategy and direction to meet client objectives. Lisa also trains, supports and leads a team of project leads and project managers.

Marjolijn van Keep

Principal Health Economist &
Country Head, Netherlands

Marjolijn joined BresMed in 2013 having completed a BSc and MSc in Pharmacy and a post-graduate certificate in International Health Technology Assessment.

Marjolijn is a senior member of the health economic analysis team. She has developed several global cost-effectiveness models and has worked on submissions to health technology assessment agencies such as NICE, the SMC, the AWMSG, the NCPE and Zorginstituut Nederland.

Miranda Cooper

Head of Statistics

Miranda joined BresMed in 2014 having completed a master’s degree in statistics from the University of Sheffield and a bachelor’s degree in mathematics from the University of Durham.

Miranda has led the development of statistical analyses to support health technology assessment (HTA) submissions and as part of standalone research. She has experience in using a range of statistical methods, such as patient level data analysis, parametric survival analysis, population adjustment techniques, crossover analysis, utility analysis and indirect treatment comparisons, including approaches that allow time-varying treatment effects.

Miranda also has experience in a range of indications – both oncology based, including melanoma, multiple myeloma, non-Hodgkin lymphoma and renal cell carcinoma – and non-oncology based, such as postpartum depression, psoriasis and epilepsy.

Nathaly Turner

Head of Communications

Nathaly joined BresMed in 2012 with over 20 years’ experience across various communications disciplines, including PR, advertising, marketing, branding, internal communications and CSR.

Nathaly leads the communications team at BresMed in developing our communications strategy to effectively engage with all our audiences, in support of our growth plans.

Renu Patel

Principal Consultant

Renu Patel joined BresMed in 2018. She has a Health Economics MSc from the University of York and an Economics BSc from City, University of London, as well as experience working in health consulting and for academic and non-profit health organisations.

In her time at BresMed, Renu has led a range of large, global HEOR workstreams in the area of differentiated thyroid carcinoma, leading updates to global SLRs, models, GVDs and an objection handler.

Richard Birnie

Head of Advanced Analytics

Richard joined BresMed in 2017 and has over 5 years of experience in health outcomes statistics, systematic reviews, meta-analysis, evidence-based medicine and survival analyses. Before moving into the field of health technology assessment (HTA), Richard worked as a research scientist; he has a PhD in molecular biology and has studied a wide range of different cancers including prostate, colorectal and medulloblastoma. Richard brings a strong understanding of fundamental biological principles in oncology and experience across a range of disease areas including ophthalmology and multiple sclerosis. He has been responsible for statistical input to HTA submissions, including survival and utility analysis. He has also worked as part of an Evidence Review Group on behalf of NICE, reviewing UK HTA submissions.

Sallie Latimer

Head of Clinical Evidence Review

Sallie has been instrumental in developing the Clinical Evidence Review team since joining BresMed in its infancy in 2010.

She has worked in clinical research for over 15 years, specifically reviewing clinical evidence in a health economics and outcomes research context for the last 8 years. Sallie’s experience includes developing value messages, and offering strategic support in demonstrating clinical benefit as part of dossier development (value and reimbursement) and primary research projects (systematic reviews, meta-analyses, targeted literature reviews and gap analyses).

Sarah Laycock

Head of Operational Support

Sarah joined BresMed in 2017 with over 20 years’ experience in the IT sector, supporting a range of businesses across several industries.

Sarah has experience in the support, design and implementation of global networks to provide productivity and efficiency benefits for operational teams.

Susan Moloney

Head of Business Development

Susan has 15 years’ experience in the healthcare industry, including 7 years in sales and marketing roles. Prior to joining BresMed in 2014, she worked in medical communications where she led account teams who developed regional and global branding, marketing and medical education initiatives.

Within BresMed, she initially worked in the communications department where she developed and led the Editorial team and supported the wider team in improving the communication quality of their deliverables. After two years on the senior management team, she transitioned to the Business Development department, where she is currently developing a global team who will work with our clients to identify their needs and connect them with the right technical teams.

Will Sullivan

Director, Health Economics Analysis

Will joined BresMed in 2014. During his PhD in Health Economics at the University of Sheffield he investigated the importance of links between different health-related behaviours for economic evaluations of strategies to change these behaviours. Before this he was a Research Associate at the University of Manchester, working on the economic evaluation of an innovative genetic testing strategy for hereditary breast cancer.

Will has extensive experience in leading health economic modelling and representing manufacturers for health technology assessment submissions to NICE, the SMC and the NCPE.

Since 2016, Will has been engaged on a contractual basis by the University of Sheffield to lecture in Health Economics as part of the Economics Department’s undergraduate programme. At BresMed, Will takes the lead on economic aspects of client projects and coordinates the Health Economic Analysis team’s technical training programme.

Yang Meng

Senior Director, Health Economic Analysis & US Head of HEAT

Yang joined BresMed in 2014 and has over 10 years of experience in health modelling and health technology assessment (HTA), spanning PhD research in infectious disease modelling, academia at ScHARR at the University of Sheffield, and health economics and outcomes research consultancy at BresMed.

He has taken responsibility for, and contributed to, economic modelling and statistical analysis for successful global and country-specific economic models and submissions to regulatory and HTA agencies including those of the UK, Ireland, US, Canada, Australia, Sweden, Spain and Italy.

By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies